Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. März 2017 16:00 ET | Quelle: NOVARTIS FINANCE S.A.

Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review

Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cells Novartis made an early commitment to the...
22. März 2017 02:15 ET | Quelle: NOVARTIS FINANCE S.A.

Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure

Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to...
13. März 2017 15:07 ET | Quelle: NOVARTIS FINANCE S.A.

Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] At...
25. Januar 2017 12:31 ET | Quelle: NOVARTIS FINANCE S.A.

NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2016

As filed with the US Securities and Exchange Commission on January 25, 2017 ...
25. Januar 2017 01:00 ET | Quelle: NOVARTIS FINANCE S.A.

Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback

FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance Cosentyx (USD 1.1 billion) reached blockbuster status Entresto (USD 170 million) continued to grow...
12. Dezember 2016 01:00 ET | Quelle: NOVARTIS FINANCE S.A.

Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)

Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care...
01. November 2016 02:15 ET | Quelle: NOVARTIS FINANCE S.A.

Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer

Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared...
25. Oktober 2016 01:00 ET | Quelle: NOVARTIS FINANCE S.A.

Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters

Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD...
18. September 2016 16:00 ET | Quelle: NOVARTIS FINANCE S.A.

Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients

EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary...
25. August 2016 01:15 ET | Quelle: NOVARTIS FINANCE S.A.

Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS

The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression...

Vorherige Seite